A Double-blind Placebo Controlled, Randomized, Phase II Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients

Trial Profile

A Double-blind Placebo Controlled, Randomized, Phase II Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs Teslexivir (Primary)
  • Indications Condylomata acuminata
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Anaconda Pharma
  • Most Recent Events

    • 31 Aug 2017 According to an Aviragen Therapeutics media release, the company anticipates to complete the enrolment in this trial in the fourth quarter of calendar year 2017. Top-line safety and efficacy data is expected in the second quarter of calendar year 2018.
    • 04 Apr 2017 According to an Aviragen Therapeutics media release, the company anticipates top-line efficacy data in the first half of 2018.
    • 04 Apr 2017 According to an Aviragen Therapeutics media release, the company anticipates to complete the enrolment in this trial in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top